Co-Stimulatory Bispecific Engagers for the Treatment of Solid Tumors

• Developing a suite of CD28 agonistic antibodies optimized for bispecific engineering to target solid tumors
• Addressing the limited translation of transformative outcomes of T-cell engagers in hematologic cancers, into solid tumors
• Integrating CD28 costimulation into bispecific therapeutics to enhance T-cell effector function and drive robust anti-tumor responses in the solid tumor setting

Speakers:

Elaine Chen

Senior Scientist, Translational Biology

Rondo Therapeutics